<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02158559</url>
  </required_header>
  <id_info>
    <org_study_id>DH-140318-01</org_study_id>
    <nct_id>NCT02158559</nct_id>
  </id_info>
  <brief_title>the Effect of Danhong Injection on Microcirculation in the Treatment of Patients With STEMI After the PTCA Surgery.</brief_title>
  <acronym>Danhong</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of the Effect of Danhong Injection on Microcirculation in the Treatment of Patients With STEMI(ST- Elevation Myocardical Infarction) After the PTCA Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Bozhiyin T&amp;S Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Bozhiyin T&amp;S Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study focused on the effect of Danhong injection on microcirculation in the treatment of
      patients with STEMI(ST-elevation myocardical infarction) after the PTCA surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research Topic.

        -  A randomized, double-blind, placebo-controlled, multi-center clinical trial of the
           effect of Danhong Injection on microcirculation in the treatment of patients with
           STEMI(ST- elevation myocardical infarction) after the PTCA surgery.

      Research Purpose.

        -  This study focused on the effect of Danhong injection on microcirculation in the
           treatment of patients with STEMI(ST-elevation myocardical infarction) after the PTCA
           surgery.

      Research design.

        -  A randomized, double-blind, placebo-controlled, multi-center clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>After 7 days surgery used magnetic resonance assessed myocardial perfusion and myocardial function.</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Danhong Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Danhong injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danhong Injection</intervention_name>
    <description>Danhong injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;</description>
    <arm_group_label>Danhong Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;</description>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically definite or laboratory-supported diagnosis of STEMI ,with the indication of
             PTCA surgery.

          -  18≤Age≤75;

          -  Agreed to join in the study and signed the inform consent form.

        Exclusion Criteria:

          -  Cardiogenic shock , Killip III-IV degree , papillary muscle rupture , septal
             perforation , episodes of ventricular tachycardia and ventricular fibrillation after
             electrical cardioversion , temporary pacemaker implanted AVB III degree.

          -  Past history of PCI and CABG

          -  Acute or chronic infectious diseases(for example severe pneumonia);

          -  Recent history of hemorrhagic stroke(within six months)

          -  Combined with liver and kidney dysfunction;

          -  History of valvular heart disease;

          -  Congenital heart disease or Pulmonary hypertension;

          -  All kinds of history of cardiomyopathy;

          -  Bleeding and other thrombotic diseases;

          -  Severe anemia , thrombocytopenia , Other diseases of the blood system;

          -  Cancer , Autoimmune disease , All kinds of the patients who use the glucocorticoid and
             immunosuppressor;

          -  Menstrual period women, pregnant women and lactating women, pregnancy test positive or
             recent family planning.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2014</study_first_submitted>
  <study_first_submitted_qc>June 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2014</study_first_posted>
  <last_update_submitted>June 5, 2014</last_update_submitted>
  <last_update_submitted_qc>June 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

